Actualités

Centene's improved medical-cost ratio supported substantially higher annual earnings and revenue expectations.

Centene (NYSE:CNC) raised its full-year 2026 adjusted earnings outlook after reporting second-quarter results that exceeded its prior expectations, supported by Marketplace risk-adjustment developments, stronger Medicare performance and continued progress on Medicaid rates. The company reported adj

CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.

S&P 500 health insurer Centene blew away Q2 earnings forecasts amid lower-than-expected Affordable Care Act Marketplace benefit costs. CNC stock initially moved higher, but shares reversed sharply lower as the company discussed its outlook, including slightly higher Medicaid attrition and a more costly covered population in the second half of 2026. Centene posted Q2 earnings of $2.51 a share, crushing forecasts of $1.09 by $1.42 a share.

Although the revenue and EPS for Centene (CNC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The managed care giant raised its 2026 earnings outlook for the second time this year following the results, which its CFO called “fantastic.”

Centene Corporation (NYSE:CNC) reported better-than-expected second-quarter results on Tuesday, delivering earnings and revenue that comfortably exceeded Wall Street forecasts as improved performance across its Medicare and Commercial businesses supported a stronger full-year outlook. Shares of the health insurer rose 3.

Centene (CNC) delivered earnings and revenue surprises of +182.02% and +12.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Centene lifted its guidance for the year after revenue and profit growth in the second quarter were driven by strength in its core government-sponsored and individual healthcare lines.

Health coverage company Centene (NYSE:CNC) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.9% year on year to $53.58 billion. The company’s full-year revenue guidance of $195.5 billion at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP profit of $2.51 per share was significantly above analysts’ consensus estimates.

Today Earnings (a.m.): Coca-Cola, UPS, Boeing, Sherwin-Williams, Hilton, Centene, PayPal, S&P Global Earnings (p.m.): Visa, Ford Motor, Mondelez International, Waste Management, PPG Industries, Bloom Energy, Avis Budget, Seagate Technology Economic data: Consumer confidence index, Johnson Redbook retail sales index, U.

Health coverage company Centene (NYSE:CNC) will be reporting results this Tuesday before market open. Here’s what you need to know.

The healthcare giant looks expensive on today's numbers, but a patient investor is effectively buying it at a significant discount to that price.

Beyond analysts' top-and-bottom-line estimates for Centene (CNC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

CNC reports Q2 results July 28 as investors weigh improving profitability against membership declines and revenue pressure ahead of earnings.

Investors are rightly focused on the company's Medicaid struggles, but the real upside story may be hiding in plain sight across the rest of its business.

UnitedHealth's stock is flying high after it raised guidance, but on its latest earnings call, analysts zeroed in on an underlying margin divergence running right through the business.

The stock is trading near 52-week highs, but under the surface, commercial segment cost trends are creating headwinds.

The health insurer raised its forecast after a solid quarter, but investors focused on the one business so broken it’s forcing a strategic retreat.

Centene’s updated price target framework now reflects a fair value revision from US$61.83 to US$63.78, a modest uplift that has caught investor attention. Research commentary links this shift to a more constructive view on Centene’s earnings power, supported by trends in exchanges, Medicare Advantage, and early signs of Medicaid margin recovery, while still pointing out execution and policy risks. As you read on, you will see how this evolving analyst narrative may matter for your own view of...

Elevance Health raised its profit forecast and the stock promptly fell. Here’s the one number that explains why investors headed for the exits.

The core narrative surrounding UnitedHealth Group (UNH) is dominated by its successful margin recovery, yet the underlying data reveal a shift from a growth compounder to a vulnerable margin defender. The defining insight is not the massive bottom-line beat of a $6.38 adjusted earnings per share against a $4.94 consensus estimate. Rather, it is the deliberate contraction of the core membership base to support margins in the face of significant regulatory headwinds.

The stock is priced for strength, but a deep and persistent drag from one of its largest divisions could challenge the optimistic narrative.

UnitedHealth Group crushed Q2 earnings forecasts amid lower-than-expected benefit costs and gave a big boost to its full-year outlook. Humana, Centene and CVS Health all got a sizable lift from the warm reception for UnitedHealth's earnings report.

The healthcare giant posts better-than-expected second-quarter earnings and hikes its full-year guidance.

Skittish investors pushed Elevance shares down, as they focused on worries about its Medicaid business. CEO Gail Boudreaux said the insurer’s Medicaid results were roughly what it expected, but the company is leaving the District of Columbia’s Medicaid market and plans to exit others over the next year to 18 months.

Elevance Health topped Q2 earnings estimates Wednesday, despite falling medical membership, but profit was boosted by one-time "below-the-line" factors and the full-year outlook was underwhelming. ELV stock tumbled, making it among the S&P 500's early laggards. Molina Healthcare, another S&P 500 managed care stock, joined Elevance among the biggest laggards performers in pre-market trading.

Investing.com -- Elevance Health’s Health Benefits operating profit collapsed in the second quarter of 2026, igniting a broad premarket selloff across the managed-care sector even as the insurer’s headline earnings handily beat estimates and full-year guidance was lifted.

Elevance Health is breaking the Medicare Advantage curse, and the insurer’s earnings could show it on Wednesday. Health insurer stocks have rallied this year after a tough run of rising medical costs that hampered earnings in 2024 and 2025. The results come just a day ahead of the monster of the industry, UnitedHealth Group Wall Street will be watching to see if these two companies can keep the momentum going.

Chevron's long-term growth drivers face regulatory, geopolitical and valuation hurdles, prompting a cautious stance despite solid operational strengths.